Retevmo
E561040
Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Retevmo canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003735 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Retevmo Context triple: [Loxo Oncology, secondMajorProductMarketedName, Retevmo]
-
A.
Eltigen
Eltigen is a coastal village on the Kerch Peninsula in Crimea, historically notable as a key site of Soviet amphibious landings during World War II.
-
B.
Reitia
Reitia is an ancient goddess venerated by the Veneti people of northeastern Italy, often linked to writing, healing, and protection.
-
C.
Soline
Soline is a small coastal village on the Croatian island of Krk, known for its tranquil bays and Adriatic seaside setting.
-
D.
Norval
Norval is a small historic village in Ontario, Canada, known for its scenic Credit River setting and association with author Lucy Maud Montgomery.
-
E.
Reitoca
Reitoca is a municipality in southern Honduras known for its rural character and location within the Francisco Morazán Department.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Retevmo Target entity description: Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.
-
A.
Eltigen
Eltigen is a coastal village on the Kerch Peninsula in Crimea, historically notable as a key site of Soviet amphibious landings during World War II.
-
B.
Reitia
Reitia is an ancient goddess venerated by the Veneti people of northeastern Italy, often linked to writing, healing, and protection.
-
C.
Soline
Soline is a small coastal village on the Croatian island of Krk, known for its tranquil bays and Adriatic seaside setting.
-
D.
Norval
Norval is a small historic village in Ontario, Canada, known for its scenic Credit River setting and association with author Lucy Maud Montgomery.
-
E.
Reitoca
Reitoca is a municipality in southern Honduras known for its rural character and location within the Francisco Morazán Department.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
Japan NERFINISHED ⓘ United States NERFINISHED ⓘ |
| belongsToPharmacologicClass | selective RET inhibitor ⓘ |
| contraindicatedWith | severe hypersensitivity to selpercatinib ⓘ |
| developedBy | Eli Lilly and Company NERFINISHED ⓘ |
| hasActiveIngredient | selpercatinib ⓘ |
| hasApprovalType | FDA accelerated approval ⓘ |
| hasATCCode | L01EX19 ⓘ |
| hasBlackBoxWarning | hepatotoxicity ⓘ |
| hasCommonAdverseEffect |
constipation
ⓘ
diarrhea ⓘ dry mouth ⓘ edema ⓘ elevated liver enzymes ⓘ fatigue ⓘ hypertension ⓘ |
| hasDosageForm | capsule ⓘ |
| hasDrugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| hasHalfLife | approximately 32 hours ⓘ |
| hasInternationalNonproprietaryName | selpercatinib NERFINISHED ⓘ |
| hasPregnancyRisk | may cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasWarning |
QT interval prolongation
ⓘ
hemorrhagic events ⓘ hypersensitivity reactions ⓘ hypertension ⓘ risk of impaired wound healing ⓘ |
| indicatedFor |
RET fusion-positive non-small cell lung cancer
ⓘ
RET fusion-positive thyroid cancer ⓘ RET-mutant medullary thyroid cancer ⓘ advanced RET fusion-positive thyroid carcinoma ⓘ advanced medullary thyroid carcinoma with RET mutation ⓘ metastatic non-small cell lung cancer with RET gene fusion ⓘ |
| mechanismOfAction | selective RET kinase inhibition ⓘ |
| metabolizedBy | CYP3A4 NERFINISHED ⓘ |
| regulatesPathway | RET signaling pathway ⓘ |
| requiresCompanionDiagnostic | RET gene alteration testing ⓘ |
| targetsGene | RET ⓘ |
| usedIn |
adult patients
ⓘ
pediatric patients 12 years and older ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Retevmo Description of subject: Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology